Literature DB >> 19269675

Immunohistochemical characterization of mullerian mucinous borderline tumors: possible histogenetic link with serous borderline tumors and low-grade endometrioid tumors.

Masafumi Yasunaga1, Yoshihiro Ohishi, Yoshinao Oda, Munechika Misumi, Atsuko Iwasa, Shuichi Kurihara, Izumi Nishimura, Emi Okuma, Hiroaki Kobayashi, Norio Wake, Masazumi Tsuneyoshi.   

Abstract

Mullerian mucinous borderline tumor and gastrointestinal mucinous borderline tumor are considered mucinous tumor subtypes. However, it has been reported that mullerian mucinous borderline tumor shares many clinicopathologic features with serous borderline tumor. Furthermore, some investigators have explained the histogenesis of mullerian mucinous borderline tumor by metaplastic and hyperplastic transformation of endometriosis (Fukunaga M, Ushigome S. Epithelial metaplastic changes in ovarian endometriosis. Mod Pathol. 1998;11:784-788). The purpose of this study is to substantiate the concept that mullerian mucinous borderline tumor is histogenetically closer to serous borderline tumor or low-grade endometrioid tumor than to gastrointestinal mucinous borderline tumor by directly comparing their immunophenotype. A total of 80 cases of low-grade ovarian tumors composed of 20 mullerian mucinous borderline tumors, 20 gastrointestinal mucinous borderline tumors, 20 serous borderline tumors, and 20 low-grade endometrioid tumors were immunohistochemically evaluated for the expression of estrogen receptor, progesterone receptor, vimentin, WT-1, beta-catenin, and PTEN. Almost all cases of mullerian mucinous borderline tumor, serous borderline tumor, and low-grade endometrioid tumor showed diffuse and strong nuclear expression of estrogen receptor and progesterone receptor. In addition, about half of the mullerian mucinous borderline tumor, serous borderline tumor, and low-grade endometrioid tumor cases showed focal but strong vimentin cytoplasmic expression. In contrast, gastrointestinal mucinous borderline tumor showed no expression of estrogen receptor, progesterone receptor, or vimentin, except for 1 case in which estrogen receptor expression was very focally and weakly observed. WT-1 nuclear expression was observed in most serous borderline tumors and only 15% of low-grade endometrioid tumor, but mullerian and gastrointestinal mucinous borderline tumor cases were completely negative. beta-Catenin nuclear expression was significantly more frequent in low-grade endometrioid tumor than in mullerian mucinous borderline tumor, gastrointestinal mucinous borderline tumor, or serous borderline tumor. PTEN expression was significantly lower in low-grade endometrioid tumor than in mullerian mucinous borderline tumor, gastrointestinal mucinous borderline tumor, and serous borderline tumor. Multiple comparisons of quantitative immunoreactivities of estrogen receptor, progesterone receptor, and vimentin revealed that the gastrointestinal mucinous borderline tumor expression profiles were significantly different from those of mullerian mucinous borderline tumors, serous borderline tumors, and low-grade endometrioid tumors. The immunohistochemical expression profiles of estrogen receptor, progesterone receptor, and vimentin substantiate the concept that the histogenesis of mullerian mucinous borderline tumor is closer to those of serous borderline tumor and low-grade endometrioid tumor than to that of gastrointestinal mucinous borderline tumor. However, aberrant beta-catenin and PTEN protein expression, both of which are known to contribute to the tumorigenesis of low-grade endometrioid tumor, appeared to be less important for the tumorigenesis of mullerian mucinous borderline tumor.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19269675     DOI: 10.1016/j.humpath.2008.12.006

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  9 in total

1.  Differential vimentin expression in ovarian and uterine corpus endometrioid adenocarcinomas: diagnostic utility in distinguishing double primaries from metastatic tumors.

Authors:  Mohamed M Desouki; Sarah J Kallas; Dineo Khabele; Marta A Crispens; Omar Hameed; Oluwole Fadare
Journal:  Int J Gynecol Pathol       Date:  2014-05       Impact factor: 2.762

2.  Ovarian Seromucinous Borderline Tumors Are Histologically Different from Mucinous Borderline Tumors.

Authors:  Taira Hada; Morikazu Miyamoto; Hiroki Ishibashi; Haruka Kawauchi; Hiroaki Soyama; Hiroko Matsuura; Takahiro Sakamoto; Soichiro Kakimoto; Tadashi Aoyama; Hideki Iwahashi; Rie Suzuki; Hitoshi Tsuda; Masashi Takano
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

Review 3.  Pathogenesis and the role of ARID1A mutation in endometriosis-related ovarian neoplasms.

Authors:  Daichi Maeda; Ie-Ming Shih
Journal:  Adv Anat Pathol       Date:  2013-01       Impact factor: 3.875

4.  Peroxiredoxins, thioredoxin, and Y-box-binding protein-1 are involved in the pathogenesis and progression of dialysis-associated renal cell carcinoma.

Authors:  Fumiyoshi Fushimi; Kenichi Taguchi; Hiroto Izumi; Kimitoshi Kohno; Michihiko Kuwano; Mayumi Ono; Yutaka Nakashima; Tetsuro Takesue; Seiji Naito; Yoshinao Oda
Journal:  Virchows Arch       Date:  2013-08-02       Impact factor: 4.064

Review 5.  Endometriosis and ovarian cancer: a review of clinical, pathologic, and molecular aspects.

Authors:  Jian-Jun Wei; Josette William; Serdar Bulun
Journal:  Int J Gynecol Pathol       Date:  2011-11       Impact factor: 2.762

6.  Invasive recurrence of an intestinal-type mucinous epithelial neoplasm of low malignant potential: case report and review of the literature.

Authors:  S Cosyns; M Leyder; C Bourgain; P De Sutter
Journal:  Case Rep Oncol       Date:  2011-08-31

Review 7.  Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria.

Authors:  Steffen Hauptmann; Katrin Friedrich; Raymond Redline; Stefanie Avril
Journal:  Virchows Arch       Date:  2016-12-27       Impact factor: 4.064

8.  Use of tumor markers to distinguish endometriosis-related ovarian neoplasms from ovarian endometrioma.

Authors:  Hiroki Shinmura; Koichi Yoneyama; Eika Harigane; Yohei Tsunoda; Takehiko Fukami; Takashi Matsushima; Toshiyuki Takeshita
Journal:  Int J Gynecol Cancer       Date:  2020-04-30       Impact factor: 3.437

Review 9.  Ovarian Seromucinous Tumors: Pathogenesis, Morphologic Spectrum, and Clinical Issues.

Authors:  Michiko Nagamine; Yoshiki Mikami
Journal:  Diagnostics (Basel)       Date:  2020-01-31
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.